Zylox-Tonbridge, a Hong Kong-listed medical technology company, has signed a definitive agreement to acquire Optimed Medizinische Instrumente GmbH, a Germany-based vascular device specialist.
The transaction will be executed in multiple steps. Zylox-Tonbridge has the option to acquire 100% equity in Optimed from existing shareholders.
Who Is Optimed—and Why It Matters?
Founded in 1996 and headquartered in Ettlingen, Germany, Optimed focuses on minimally invasive vascular and endourology devices.
Over nearly 30 years, Optimed has built:
- Sales and service coverage across 70+ countries
- Deep relationships with European physicians and key opinion leaders
- One of the most comprehensive peripheral venous stent portfolios globally
Its venous stents target complex anatomies, including:
- Iliofemoral veins
- Iliac bifurcation
- Vena cava
Strong Clinical Evidence
Optimed’s products are backed by high-quality clinical data, including:
- sinus-Venous trial
- STEVECO trial, the first prospective, randomized, multicenter study in chronic deep venous obstruction
The STEVECO trial showed significant improvements in quality of life and clinical severity versus conservative treatment.
Strategic Rationale Behind the Acquisition
The acquisition creates a fully integrated global platform across R&D, manufacturing, and commercialization.
Key strategic advantages include:
- Faster global product launches
- Expanded access to European clinical expertise
- Stronger presence beyond mainland China
Following closing, Zylox-Tonbridge will integrate sales, marketing, and customer service into one global commercial organization.
Rüdiger Hausherr will remain CEO of Optimed and report to Dr. Jonathon Zhong Zhao, Chairman and CEO of Zylox-Tonbridge.
Leadership Commentary
Dr. Jonathon Zhong Zhao called the acquisition a milestone in Zylox-Tonbridge’s global strategy.
He emphasized combining complementary product portfolios and manufacturing platforms to deliver innovative and affordable vascular solutions worldwide. Optimed CEO Rüdiger Hausherr highlighted the need to evolve amid changing healthcare dynamics.
He noted the partnership enables Optimed to scale faster by leveraging Zylox-Tonbridge’s R&D and manufacturing strength. Westlake Partners, Optimed’s investor, described Zylox-Tonbridge as a fast-growing multinational with strong roots in China and proven global execution.
Key Transaction Benefits
1. Accelerated Global Expansion
- Strengthens Zylox-Tonbridge’s footprint in Europe and international markets
- Diversifies product portfolio and global distribution
2. Integrated Global Commercialization
- Combines two complementary sales networks
- Supports faster clinical development and efficient launches
3. Manufacturing and Operational Synergies
- Integrated production across Germany and China
- Expanded German manufacturing ensures high-quality, reliable supply for Europe
4. Scaled Global R&D Impact
- Enables Zylox-Tonbridge to extend its high-efficiency R&D globally
- Supports a sustained pipeline of advanced vascular solution
Company Snapshot
Zylox-Tonbridge Medical Technology Co., Ltd.
- Founded: 2012
- Headquarters: Hangzhou, China
- Focus: Vascular interventional medical devices
Optimed Medizinische Instrumente GmbH
- Founded: 1996
- Headquarters: Ettlingen, Germany
- Focus: Minimally invasive vascular and endourology devices
- Global leader in venous stenting
Bottom Line
This acquisition positions Zylox-Tonbridge as a truly global vascular device player, combining European clinical leadership with China-based R&D and manufacturing scale.
